Showing results (51-60 of 588) with videos related to
Sort By:
Pageof 59
Cancer Journal (Sudbury, Mass.)|March 25, 2024
What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?Matthew J Hadfield, Ryan J SullivanFuture Oncology (London, England)|August 5, 2017
Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeuticsMeghan J Mooradian, Ryan J SullivanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2015
Pembrolizumab for Treatment of Patients with Advanced or Unresectable MelanomaRyan J Sullivan, Keith T FlahertyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2015
New strategies in melanoma: entering the era of combinatorial therapyRyan J Sullivan, Keith T FlahertyOncology (Williston Park, N.Y.)|April 17, 2019
What to Do When Anti-PD-1 Therapy Fails in Patients With MelanomaMeghan J Mooradian, Ryan J SullivanMelanoma Management|September 8, 2018
Biomarkers in melanoma: where are we now?Douglas B Johnson, Ryan J SullivanCancers|August 26, 2023
Immunotherapy in Melanoma: Recent Advancements and Future DirectionsMeghan J Mooradian, Ryan J SullivanThe Journal of Organic Chemistry|March 24, 2020
Reaction Cycling for Kinetic Analysis in FlowRyan J Sullivan, Stephen G NewmanNature Reviews. Drug Discovery|July 28, 2021
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategiesRyan J Sullivan, Jeffrey S WeberCancer|June 22, 2023
The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanomaMeghan J Mooradian, Ryan J SullivanPageof 59